In a sign that China’s dedication to boosting its domestic healthcare industry remains as strong as ever, three Chinese investment firms have recently announced a 150 million USD investment in CStone Pharmaceuticals Co., Ltd., a bio-pharmaceutical company that is developing new treatments for major diseases.
The research-based company was founded in Shanghai and Suzhou. Its treatments cover oncology, cardiovascular diseases, hematology, rheumatoid arthritis and autoimmune diseases. It focuses, particularly on immuno-oncology. Frank Jiang, former head of Asia-Pacific R&D at Sanofi, has been appointed as CStone’s new CEO.
The company’s three new investors are Oriza Seed Venture Capital, a unit of Suzhou Oriza Holdings Ltd.; Boyu Capital, a private investment firm based in Beijing and Hong Kong, and WuXi Healthcare Ventures, a Chinese cross-border venture capital firm focused on healthcare and life sciences.
Naseba has established close ties with investors based in China. These investors are currently looking to invest in foreign healthcare opportunities within a variety of subsectors, including pharmaceuticals and medical technology.
On July 27th, 2016, Naseba will be hosting the Healthcare Investors Meeting in Beijing. At the meeting, pre-screened Chinese investors will be introduced to pre-qualified healthcare investment opportunities from around the world. To learn more, contact:
Naseba investor introduction
+971 4 455 7954